Enrolment Number										
------------------	--	--	--	--	--	--	--	--	--	--

Total No. of printed pages = 01

Monsoon, 2023

M.Pharm (Pharmaceutics) Semester Examinations

REGULATORY AFFAIR

Course Code: MPH104T

Full Marks - 75 Time - Three hours

The figure in the margin indicates full marks for the questions.

I. Answer all the questions (Within 50 words)

 $(10 \times 2 = 20)$

- 1. Explain the significance of 21CFR part 314?
- 2. What are the key distinctions between IND, NDA, and ANDA applications?
- 3. How does the Orange Book contribute to the pharmaceutical industry?
- 4. Identify the regulatory bodies responsible for drug regulation in India and the USA.
- 5. Define the term "dossier" in the context of Drug Regulatory Affairs.
- 6. In what ways do distribution records play a role in supporting regulatory affairs?
- 7. What is the purpose of an Investigator Brochure in clinical research?
- 8. Elaborate on the importance of Pharmacovigilance safety monitoring in clinical studies.
- 9. Why is Drug Regulatory Affairs considered important in the pharmaceutical field?
- 10. Differentiate between a Generic drug product and an Innovator drug product?

II. Answer any seven questions (Within 500 words)

 $(7 \times 5 = 35)$

- 1. Explain the *In-vitro* drug product performance.
- 2. Can you provide a detailed explanation of the responsibilities of institutional review boards/independent ethics committees in clinical trials?
- 3. Elaborate on the key components of an investigator brochure used in clinical research.
- 4. Describe the pharmaceutical distribution system in India and its intricacies.
- 5. How does HIPAA contribute to the effectiveness of clinical trials, and what is its relevance?
- 6. Provide examples to illustrate various activities performed by CROs in the pharmaceutical industry.
- 7. Explain the process of handling post-approval changes in approved ANDAs.
- 8. What does MFR stand for, and what are the contents of a Master File in the pharmaceutical context?
- 9. Discuss the utility of the Hatch-Waxman Act and its impact on the pharmaceutical landscape.

III. Answer any two questions (Within 1000 words)

 $(2 \times 10 = 20)$

- 1. Describe the regulatory requirements for ICH guidelines with special reference to ICH-Q, S, E, M
- 2. Give a detailed account of documentation in pharmaceutical industries with suitable examples.
- 3. Write in detail about developing clinical trial protocols and other working procedures for conducting clinical trials.